Drug Discov. 7 426–437; 2008). Increased levels of glutamate have been found in the frontal cortex of patients with MDD, and the non-selective NMDA receptor antagonist ketamine has shown ...

NMDA receptors are present throughout the brain and are essential for maintaining consciousness. For this reason, she ...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...

Dr Price has previously run a study combining ASAT with ketamine, which showed that a single infusion of the drug followed ... the only FDA-approved NMDA receptor antagonist for depression ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

INR:1645. t20 world cup list india team Exploring the current status of unprofitable pharmaceutical companies listed in Hong Kong New depression dru ...